n-Lorem Foundation Welcomes New Member Alan Lotvin to Its Board of Directors
2024年5月9日 - 10:05PM
ビジネスワイヤ(英語)
Alan Lotvin’s expertise in pharmacy benefit management and
specialty pharmacy industries will inform n-Lorem’s efforts to
identify and implement solutions to support nano-rare patient
treatments
n-Lorem, a nonprofit foundation, discovering, developing and
providing experimental antisense oligonucleotide (ASO) medicines
for nano-rare patients (1 to 30 patients worldwide) for free, for
life, today announced that Alan Lotvin, M.D., has joined its Board
of Directors.
“Stan and the entire n-Lorem team have created an organization
unlike any I have been involved in. With a commitment to quality
and patient safety at the top of any decision, n-Lorem has
implemented an efficient and scalable process to discover, develop
and provide personalized ASO medicines to patients today,” Dr.
Lotvin said. “This work has already changed the lives of many
people who have had no other options available to them. It is work
like this that led me to get into medicine and work to bring new
advancements to the world. I look forward to joining the Board of
Directors and helping n-Lorem continue to identify and implement
creative solutions to reach even more nano-rare patients.”
“At n-Lorem, we have expanded years ahead of where we
anticipated due to the overwhelming demand from the nano-rare
community. As we identify and implement efficiencies in one area of
the organization, more challenges present. Alan’s deep
understanding and experience with healthcare coverage and insurers
will help inform our efforts as we scale to meet a growing need
from the nano-rare community,” said Stanley T. Crooke, M.D., Ph.D.,
Founder, Chairman and CEO, n-Lorem Foundation. “While we are
currently helping individual patients, we will one day be able to
treat thousands of patients with nano-rare conditions. Our Board is
going to be an integral part of ensuring we can reach that
goal.”
Learn more about n-Lorem’s mission at www.nlorem.org, and please
consider giving to n-Lorem to bring hope, possibility and treatment
options to these needy patients and families.
Watch: n-Lorem Foundation: Offering Hope and Help to Nano-rare
Patients Watch: n-Lorem Foundation Delivers Hope and Treatment for
Patient with Nano-Rare Disease
About Alan Lotvin
Dr. Lotvin is an interventional cardiologist with extensive
experience in pharmacy benefit management and specialty pharmacy
industries. Alan Lotvin co-founded Sequel, a company developing
state-of-the-art insulin delivery technologies. Prior to Sequel,
Dr. Lotvin served as executive vice president of CVS Health and
president of CVS Caremark, the company’s pharmacy benefits
management business. He was also the chief transformation officer
and executive vice president of CVS Speciality, the specialist
pharmacy of CVS Health, and held roles in ICORE Healthcare and Medo
Health Solutions. Dr. Lotvin started his career as a cardiologist
in New Jersey. Dr. Lotvin holds a Masters Degree in Medical
Informatics from Columbia University, a Medical Degree from the
State University of New York Health Sciences Center in Brooklyn,
and a bachelor’s degree in biochemistry from Stony Brook
University.
About n-Lorem
n-Lorem Foundation is a non-profit organization established to
apply the efficiency, versatility and specificity of antisense
technology to charitably provide experimental antisense
oligonucleotide (ASO) medicines to treat nano-rare patients
diagnosed with diseases that are the result of a single genetic
defect unique to only one or very few individuals. Nano-rare
patients describe a very small group of patients (1-30 worldwide)
who, because of their small numbers, have few if any treatment
options. n-Lorem Foundation was created to provide hope to these
nano-rare patients by developing individualized ASO medicines,
which are short strands of modified DNA that can specifically
target the transcripts of a defective gene to correct the
abnormality. The advantage of experimental ASO medicines is that
they can be developed rapidly, inexpensively and are highly
specific. To date, n-Lorem received over 260 applications for
treatment with more than 120 nano-rare patients approved. n-Lorem
was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and
CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in
1989 and, through his vision and leadership, established the
company as the leader in RNA-targeted therapeutics. Follow us on
Twitter, Facebook, LinkedIn and YouTube.
Learn more about n-Lorem’s mission at www.nlorem.org, and please
consider giving to n-Lorem to bring hope, possibility and treatment
options to these patients and families in need.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240509612084/en/
n-Lorem Contact: Amy Williford, Ph.D. Sr. Director of
Communications amy.williford@nlorem.org